...NEW YORK (Standard & Poor's) May 7, 2015--Standard & Poor's Ratings Services today assigned its '###-' issue-level ratings to Marlborough, Mass.-based medical device company Boston Scientific Corp.'s planned issuance of senior notes with a mix of maturities. We expect the company to primarily use the proceeds to fund a portion of the acquisition of Endo International PLC's Men's Health and Prostrate Health businesses and to refinance certain outstanding debt obligations. Our '###-' corporate credit rating on Boston Scientific reflects our assessment of the company's business risk as "strong" and the financial risk profile as "aggressive". The outlook is negative, reflecting credit measures which are quite weak for the rating, and downside risk to the base-case expectation of rapid deleveraging over the next two years. Our assessment of the company's "strong" business risk profile reflects the company's broad portfolio of market-leading medical devices used in diverse specialties, an expansive...
